Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting

Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Belaroussi, Yaniss, Bouteiller, Fanny, Bellera, Carine, Pasquier, David, Perol, Maurice, Debieuvre, Didier, Filleron, Thomas, Girard, Nicolas, Schott, Roland, Mathoulin-Pélissier, Simone, Martin, Anne-Laure, Cousin, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264352/
https://www.ncbi.nlm.nih.gov/pubmed/37311845
http://dx.doi.org/10.1038/s41598-023-36623-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264352/
https://www.ncbi.nlm.nih.gov/pubmed/37311845
http://dx.doi.org/10.1038/s41598-023-36623-1

Ejemplares similares